No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
SXTP 60 Degrees Pharmaceuticals
- 0.240
- -0.018-6.94%
Close Jul 2 16:00 ET
- 0.250
- +0.010+4.12%
Post 18:28 ET
2.93MMarket Cap-2791P/E (TTM)
0.258High0.240Low147.13KVolume0.244Open0.258Pre Close35.82KTurnover1.63%Turnover RatioLossP/E (Static)12.21MShares8.65052wk High-1.10P/B2.17MFloat Cap0.20152wk Low--Dividend TTM9.02MShs Float8.650Historical High--Div YieldTTM6.90%Amplitude0.201Historical Low0.243Avg Price1Lot Size
Full Hours
- 5D
- Daily
- Weekly
- Monthly
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Express News | First Patient Enrolled in 60 Degrees Pharmaceuticals Clinical Trial of Tafenoquine for Babesiosis at Tufts Medical Center; First and Only Study of Its Kind
Express News | 60 Degrees Pharmaceuticals Shares Are Trading Higher After the Company Announced FDA Orphan Drug Designation for Tafenoquine to Treat Acute Babesiosis
Express News | 60 Degrees Pharmaceuticals Receives FDA Orphan Drug Designation for Tafenoquine for Treatment of Patients With Acute Babesiosis
H.C. Wainwright Maintains 60 Degrees Pharmaceuticals(SXTP.US) With Hold Rating
H.C. Wainwright analyst Edward White maintains $60 Degrees Pharmaceuticals(SXTP.US)$ with a hold rating.According to TipRanks data, the analyst has a success rate of 30.5% and a total average return o
Express News | HC Wainwright & Co. Reiterates Neutral on 60 Degrees
60 Degrees Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 06/06/2024 — HC Wainwright & Co. Reiterates → Neutral 04/03/2024 — HC Wainwright & Co. Reiterates → Neut
Comments
$60 Degrees Pharmaceuticals(SXTP.US$
First Patient Enrolled in 60 Degrees Pharmaceuticals Clinical Trial of Tafenoquine for Babesiosis at Tufts Medical Center; First and Only Study of Its Kind
First Patient Enrolled in 60 Degrees Pharmaceuticals Clinical Trial of Tafenoquine for Babesiosis at Tufts Medical Center; First and Only Study of Its Kind
4
$60 Degrees Pharmaceuticals (SXTP.US)$ I think I'm gonna sell & be a bag holder with this instrument. Sucks. I don't feel there will be much upward movement for the next 12 months. When the Tafenquine for CFS trial with NC State Vet ends or if there is big big earnings at the end of August, I think next earnings are in August. Screw it 🔩, and I'll get back in before the CFS trial ends. I am 95% confident the results of that trial will be good. If anyone has any thoughts please ...
2
3
$60 Degrees Pharmaceuticals(SXTP.US$ 60 Degrees Pharmaceuticals Receives FDA Orphan Drug Designation for Tafenoquine for Treatment of Patients With Acute Babesiosis
$60 Degrees Pharmaceuticals(SXTP.US$ 60 Degrees Pharmaceuticals Shares Are Trading Higher After the Company Announced FDA Orphan Drug Designation for Tafenoquine to Treat Acute Babesiosis
$60 Degrees Pharmaceuticals(SXTP.US$ life always like that.. holding this for so many months , noticed almost died..today Q to sell at 0.415, and it's filled, no luck.. ( PM went up to 0.475 and down again.. shit...
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg
BAO BMW : O... hopefully this news are good for the share pricing, I bag holding this for very long time.. once it's raise above 0.286 , I will sell it's off.. at least lost a bit..Good luck
hocsheng : The daily K line has formed an upward trend
ProperMicheleVOP BAO BMW: I am a bag holder too. I am sure the share price will go up to your .286. I was gonna sell but I'm not sure now. They are doing the chronic fatigue study with NC State College of Veterinary & although that study ends next year, I think the results of it will be very positive. If Tanefoquine works for chronic fatigue that would be huge.
BAO BMW ProperMicheleVOP: thk u for the info.. appreciated